Myocardial perfusion SPECT offers 5-year warranty

April 1, 2013

The short-term prognostic benefit of myocardial perfusion scintography (MPS) is well established, and the technique also delivers long-term value up to five years after initial imaging, according to a study in the Journal of Nuclear Cardiology.

The review written by Jane A. Simonsen, MD, from the department of nuclear medicine at Odense University Hospital in Denmark, and colleagues, found few deaths and other major cardiac events after MPS evaluation of coronary artery disease.